INHBE targeting small interfering RNA - Argo Biopharma
Alternative Names: INHBE siRNA - Argo BiopharmaLatest Information Update: 04 Mar 2024
At a glance
- Originator Argo Biopharma
- Class Obesity therapies; Small interfering RNA
- Mechanism of Action INHBE protein expression modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Metabolic syndrome; Obesity
Most Recent Events
- 20 Feb 2024 INHBE targeting small interfering RNA - Argo Biopharma is available for licensing as of 20 Feb 2024. (https://www.argobiopharma.com/partnering/index.html)
- 20 Feb 2024 Preclinical trials in Metabolic syndrome in China (Parenteral) prior to February 2024 (Argo Biopharma pipeline, February 2024)
- 20 Feb 2024 Preclinical trials in Obesity in China (Parenteral) prior to February 2024 (Argo Biopharma pipeline, February 2024)